BRCA1 and rhabdomyosarcoma: For four patients with BRCA1/2 mutation who received olaparib/pembrolizumab-based combined therapy as first-line treatment (the diagnosis was SCLC, rhabdomyosarcoma, cholangiocarcinoma and pancreatic cancer, respectively), disease was well controlled with three patients achieving PR and one patient achieving SD.